Effect of the Chlorite-Based Drug WF10 on Hemoglobin A1c, Hematological Biomarkers in Uncontrolled Diabetic Patients with Foot Ulcer

Abstract

Aims: To evaluate degree and kinetics of WF10 effects on HbA1c, associated hematological biomarkers, and wound healing in uncontrolled T2DM patients with DFU. Methods: In this prospective, interventional, pretest-posttest study, 40 DFU patients with HbA1c > 8.5 % were treated with standard therapy plus five weekly infusions of the chlorite-based drug WF10 within outpatient department. Besides HbA1c kinetics, we studied red blood cell distribution width (RDW-CV) value, neutrophil-lymphocyte ratio (NLR) and wound healing at week (W) 0, 4, 8 and 12. Results: In 38 PP-treated patients WF10 decreased HbA1c value from 10.48 % at baseline (BL) to 8.06 % at W8 and Wound Severity Score (WSS) from 8.0 to 1.4 (both p < 0.0001) at W12. RDW-CV was diminished from 13.5 % to 12.8 % (p = 0.0021), NLR decreased from 2.8 to 2.2 (NS) but significantly decreased in patients with NLR > 3.5 at BL, from 6.3 to 3.2. No serious side effect of WF10 was observed. Conclusion: Standard therapy of DFU plus adjunct WF10 application consistently and long-lastingly decreased high HbA1c values and showed good outcome of wound healing in patients with uncontrolled diabetes. The used treatment protocol is applicable for outpatient treatment.